nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia
|
Torramade-Moix, Sergi |
|
|
35 |
3 |
p. 521-532 |
artikel |
2 |
Attenuation of atrial remodeling by aliskiren via affecting oxidative stress, inflammation and PI3K/Akt signaling pathway
|
Zhao, Zhiqiang |
|
|
35 |
3 |
p. 587-598 |
artikel |
3 |
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
|
Mathew, Roy O. |
|
|
35 |
3 |
p. 479-489 |
artikel |
4 |
Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients with Left Ventricular Systolic Dysfunction
|
Khan, Mahin R. |
|
|
35 |
3 |
p. 575-585 |
artikel |
5 |
Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases
|
Lee, Mei-Chuan |
|
|
35 |
3 |
p. 539-547 |
artikel |
6 |
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System
|
Kataruka, Akash |
|
|
35 |
3 |
p. 533-538 |
artikel |
7 |
Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction
|
Shaik, Aleesha |
|
|
35 |
3 |
p. 677-690 |
artikel |
8 |
Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports
|
Soumya, R. S. |
|
|
35 |
3 |
p. 411-425 |
artikel |
9 |
Integration of Transformative Platforms for the Discovery of Causative Genes in Cardiovascular Diseases
|
Lu, Haocheng |
|
|
35 |
3 |
p. 637-654 |
artikel |
10 |
Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
|
Agarwal, Shubham |
|
|
35 |
3 |
p. 427-440 |
artikel |
11 |
Major Cardiac–Psychiatric Drug–Drug Interactions: a Systematic Review of the Consistency of Drug Databases
|
Castaldelli-Maia, João Mauricio |
|
|
35 |
3 |
p. 441-454 |
artikel |
12 |
Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study
|
Larsen, Anders Hostrup |
|
|
35 |
3 |
p. 491-503 |
artikel |
13 |
Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics
|
Morales-Rosado, Joel A. |
|
|
35 |
3 |
p. 549-559 |
artikel |
14 |
Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy?
|
Arnold, Natalie |
|
|
35 |
3 |
p. 627-635 |
artikel |
15 |
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials
|
Ray, Avik |
|
|
35 |
3 |
p. 561-574 |
artikel |
16 |
Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the “Prime Time” of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?
|
Yang, Jingmin |
|
|
35 |
3 |
p. 467-477 |
artikel |
17 |
TAK1-AMPK Pathway in Macrophages Regulates Hypothyroid Atherosclerosis
|
Yang, Yunxiao |
|
|
35 |
3 |
p. 599-612 |
artikel |
18 |
Targeting Human lncRNAs for Treating Cardiometabolic Diseases
|
Ruan, Xiangbo |
|
|
35 |
3 |
p. 655-662 |
artikel |
19 |
The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight
|
Scicchitano, Pietro |
|
|
35 |
3 |
p. 505-519 |
artikel |
20 |
The Interface of Therapeutics and Genomics in Cardiovascular Medicine
|
Magavern, E. F. |
|
|
35 |
3 |
p. 663-676 |
artikel |
21 |
The Potential of Albuminuria as a Biomarker of Diabetic Complications
|
Raja, Pappitha |
|
|
35 |
3 |
p. 455-466 |
artikel |
22 |
Translating Cardiovascular Genomics to Clinical Practice
|
Chen, Y. Eugene |
|
|
35 |
3 |
p. 613-615 |
artikel |
23 |
Translating genetic association of lipid levels for biological and clinical application
|
Crone, Bradley |
|
|
35 |
3 |
p. 617-626 |
artikel |